DANONE (BSN.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BSN - FR0000120644 - Common Stock
76.04 EUR
-0.64 (-0.83%)
Overall BSN gets a fundamental rating of 5 out of 10. We evaluated BSN against 59 industry peers in the Food Products industry. BSN has an excellent profitability rating, but there are some minor concerns on its financial health. While showing a medium growth rate, BSN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year BSN was profitable.
BSN had a positive operating cash flow in the past year.
In the past 5 years BSN has always been profitable.
BSN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of BSN (4.20%) is better than 64.41% of its industry peers.
BSN's Return On Equity of 11.59% is fine compared to the rest of the industry. BSN outperforms 66.10% of its industry peers.
Looking at the Return On Invested Capital, with a value of 6.83%, BSN is in the better half of the industry, outperforming 66.10% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BSN is in line with the industry average of 7.10%.
The last Return On Invested Capital (6.83%) for BSN is above the 3 year average (6.38%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
Looking at the Profit Margin, with a value of 6.72%, BSN is in the better half of the industry, outperforming 74.58% of the companies in the same industry.
BSN's Profit Margin has been stable in the last couple of years.
BSN has a better Operating Margin (13.25%) than 77.97% of its industry peers.
BSN's Operating Margin has declined in the last couple of years.
The Gross Margin of BSN (50.47%) is better than 79.66% of its industry peers.
In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, BSN has more shares outstanding
BSN has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BSN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.54 indicates that BSN is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.54, BSN is in the better half of the industry, outperforming 64.41% of the companies in the same industry.
The Debt to FCF ratio of BSN is 5.07, which is a neutral value as it means it would take BSN, 5.07 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BSN (5.07) is better than 71.19% of its industry peers.
A Debt/Equity ratio of 0.83 indicates that BSN is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.83, BSN is not doing good in the industry: 67.80% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.54 |
ROIC/WACC1.06
WACC6.44%
2.3 Liquidity
BSN has a Current Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of BSN (0.95) is worse than 74.58% of its industry peers.
BSN has a Quick Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
BSN's Quick ratio of 0.78 is in line compared to the rest of the industry. BSN outperforms 40.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.47%.
Measured over the past years, BSN shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.17% on average per year.
BSN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.54%.
Measured over the past years, BSN shows a small growth in Revenue. The Revenue has been growing by 1.60% on average per year.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
BSN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.39% yearly.
Based on estimates for the next years, BSN will show a small growth in Revenue. The Revenue will grow by 3.16% on average per year.
EPS Next Y8%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
EPS Next 5Y6.39%
Revenue Next Year0.68%
Revenue Next 2Y1.86%
Revenue Next 3Y2.53%
Revenue Next 5Y3.16%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BSN is valuated rather expensively with a Price/Earnings ratio of 20.33.
BSN's Price/Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.41, BSN is valued a bit cheaper.
BSN is valuated rather expensively with a Price/Forward Earnings ratio of 18.18.
62.71% of the companies in the same industry are cheaper than BSN, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of BSN to the average of the S&P500 Index (35.40), we can say BSN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.33 | ||
| Fwd PE | 18.18 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSN is on the same level as its industry peers.
BSN's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.06 | ||
| EV/EBITDA | 10.99 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSN does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of BSN may justify a higher PE ratio.
PEG (NY)2.54
PEG (5Y)N/A
EPS Next 2Y7.34%
EPS Next 3Y7.61%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 2.78%. Purely for dividend investing, there may be better candidates out there.
BSN's Dividend Yield is a higher than the industry average which is at 3.35.
Compared to an average S&P500 Dividend Yield of 2.32, BSN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.78% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
BSN pays out 74.99% of its income as dividend. This is not a sustainable payout ratio.
The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP74.99%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
FRA:BSN (12/4/2025, 7:00:00 PM)
76.04
-0.64 (-0.83%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners55.49%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap51.81B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts74.84
Price Target80.89 (6.38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.78% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.83%
PT rev (3m)4.66%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.33%
EPS NY rev (3m)0.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)-0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.33 | ||
| Fwd PE | 18.18 | ||
| P/S | 1.89 | ||
| P/FCF | 18.06 | ||
| P/OCF | 13.47 | ||
| P/B | 3.27 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.99 |
EPS(TTM)3.74
EY4.92%
EPS(NY)4.18
Fwd EY5.5%
FCF(TTM)4.21
FCFY5.54%
OCF(TTM)5.64
OCFY7.42%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.54
PEG (5Y)N/A
Graham Number44.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.54 |
F-Score8
WACC6.44%
ROIC/WACC1.06
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y8%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
EPS Next 5Y6.39%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.68%
Revenue Next 2Y1.86%
Revenue Next 3Y2.53%
Revenue Next 5Y3.16%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.38%
EBIT Next 3Y14.38%
EBIT Next 5Y10.92%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%
DANONE / BSN.DE FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.
What is the valuation status of DANONE (BSN.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to DANONE (BSN.DE). This can be considered as Overvalued.
How profitable is DANONE (BSN.DE) stock?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of DANONE (BSN.DE) stock?
The Price/Earnings (PE) ratio for DANONE (BSN.DE) is 20.33 and the Price/Book (PB) ratio is 3.27.
Can you provide the expected EPS growth for BSN stock?
The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 8% in the next year.